As the JAK-blocking agents represent a novel therapeutic strategy for treating RA patients not responsive to conventional DMARDs, we investigated whether the inhibition of the JAK/STAT pathway could prevent the response observed to the heterocomplex. The gene discussed is SOAT1; the disease is rheumatoid arthritis.